Drug Profile
Multivirus-specific cytotoxic T lymphocytes - AlloVir
Alternative Names: Multivirus-specific cytotoxic T lymphocyte therapy; PrelymLatest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Baylor College of Medicine
- Class T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Adenovirus infections; Cytomegalovirus infections; Epstein-Barr virus infections; Human herpesvirus 6 infections; Polyomavirus infections
Most Recent Events
- 22 Feb 2022 No development reported - Phase-I/II for Adenovirus infections in USA (IV)
- 22 Feb 2022 No development reported - Phase-I/II for Cytomegalovirus infections in USA (IV)
- 22 Feb 2022 No development reported - Phase-I/II for Epstein-Barr virus infections in USA (IV)